Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 NCT04359095
Emtricitabine/tenofovir plus colchicine plus rosuvastatin (n=163) vs. standard of care (n=162)
randomized controlled trial
Colchicine plus rosuvastatin
Emtricitabine (200 mg) plus tenofovir disoproxil (300 mg), once a day for 10 days PO, plus colchicine, 0.5 mg twice a day, plus rosuvastatin, 40 mg once a day for 14 days PO.
Standard of care
The standard of care follows the recommendations of the Colombian Consensus forCovid-19 Treatment in Hospitalized Patients,21 consisting of the use of dexamethasone,antiparasitic treatment (ivermectin or albendazole), enoxaparin, acetaminophen, oxygen asneeded, and supportive treatment for organ failure (i.e., use mechanical ventilation, ordialysis).
COVID 19 hospitalized
Adults aged 18 years or more, with a positive real-time polymerase chain reaction (RT-PCR) or with high suspicion of SARS CoV-2 by clinical criteria and a diagnosis of mild, severe, or critical pneumonia, requiring hospital management in six high complexity referral hospitals located in Bogota.
Open-label.
6 hospitals in Bogota, Colombia.
Relative Risks adjusted for age, sex, and severity of pneumonia using g Log-binomial General Estimating Equation models, assuming exchangeable correlation structure with each center as a cluster.
